Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard versus higher starting dose of insulin glargine in overweight or obese adults with type 2 diabetes
ChiCTR-IIR-16008916Phase 4Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Overall hypoglycemic incidence. Started Jul 2016; status: recruiting.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IIR-16008916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008916.